Surya P Bhatt1, James M Wells1, Gregory L Kinney2, George R Washko3, Matthew Budoff4, Young-Il Kim5, William C Bailey1, Hrudaya Nath6, John E Hokanson2, Edwin K Silverman7, James Crapo8, Mark T Dransfield9. 1. Division of Pulmonary, Allergy and Critical Care Medicine, UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2. Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 3. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA. 5. Department of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA. 6. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 7. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 8. Division of Pulmonary and Critical Care, National Jewish Health, Denver, Colorado, USA. 9. Division of Pulmonary, Allergy and Critical Care Medicine, UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, USA Birmingham VA Medical Center, Birmingham, Alabama, USA.
Abstract
BACKGROUND: While some retrospective studies have suggested that β-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. METHODS: Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2-4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by β-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, %emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe β-blockers. RESULTS: 3464 subjects were included. During a median of 2.1 years of follow-up, β-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of β-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with β-blocker use. CONCLUSIONS: β-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. TRIAL REGISTRATION NUMBER: (ClinicalTrials.gov NCT00608764). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: While some retrospective studies have suggested that β-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. METHODS: Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2-4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by β-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, %emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe β-blockers. RESULTS: 3464 subjects were included. During a median of 2.1 years of follow-up, β-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of β-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with β-blocker use. CONCLUSIONS: β-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. TRIAL REGISTRATION NUMBER: (ClinicalTrials.gov NCT00608764). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Yvette R B M van Gestel; Sanne E Hoeks; Don D Sin; Gijs M J M Welten; Olaf Schouten; Han J Witteveen; Cihan Simsek; Henk Stam; Frans W Mertens; Jeroen J Bax; Ron T van Domburg; Don Poldermans Journal: Am J Respir Crit Care Med Date: 2008-06-19 Impact factor: 21.405
Authors: Meilan K Han; Ella A Kazerooni; David A Lynch; Lyrica X Liu; Susan Murray; Jeffrey L Curtis; Gerard J Criner; Victor Kim; Russell P Bowler; Nicola A Hanania; Antonio R Anzueto; Barry J Make; John E Hokanson; James D Crapo; Edwin K Silverman; Fernando J Martinez; George R Washko Journal: Radiology Date: 2011-07-25 Impact factor: 11.105
Authors: Michelle C Williams; John T Murchison; Lisa D Edwards; Alvar Agustí; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Jørgen Vestbo; Emiel Wouters; Julie C Yates; Edwin J R van Beek; David E Newby; William MacNee Journal: Thorax Date: 2014-01-28 Impact factor: 9.139
Authors: Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make Journal: Chest Date: 2019-05-30 Impact factor: 9.410
Authors: Surya P Bhatt; Gonzalo Vegas-Sánchez-Ferrero; Farbod N Rahaghi; Erick S MacLean; German Gonzalez-Serrano; Carolyn E Come; Gregory L Kinney; John E Hokanson; Matthew J Budoff; Michael J Cuttica; J Michael Wells; Raúl San José Estépar; George R Washko Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Mark T Dransfield; Helen Voelker; Surya P Bhatt; Keith Brenner; Richard Casaburi; Carolyn E Come; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Umur Hatipoğlu; Erika S Helgeson; Vipul V Jain; Ravi Kalhan; David Kaminsky; Robert Kaner; Ken M Kunisaki; Allison A Lambert; Matthew R Lammi; Sarah Lindberg; Barry J Make; Fernando J Martinez; Charlene McEvoy; Ralph J Panos; Robert M Reed; Paul D Scanlon; Frank C Sciurba; Anthony Smith; Peruvemba S Sriram; William W Stringer; Jeremy A Weingarten; J Michael Wells; Elizabeth Westfall; Stephen C Lazarus; John E Connett Journal: N Engl J Med Date: 2019-10-20 Impact factor: 91.245